Last reviewed · How we verify
NCT04943094: URODYN
Clinical and Functional Consequences of Photodynamic Diagnosis (PDD) and Intravesical Instillation Therapy
trial testing Urodynamic examination in Non-muscle Invasive Bladder Cancer in 50 participants. Status unknown.
31 December 2022
Quick facts
| Lead sponsor | Aarhus University Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 September 2019 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Urodynamic examination
Conditions studied
- Non-muscle Invasive Bladder Cancer — all drugs for Non-muscle Invasive Bladder Cancer →
Sponsor
Aarhus University Hospital
Who can join
Eligibility, any sex, with Non-muscle Invasive Bladder Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim is to evaluate and compare treatment strategies for non-muscle invasive bladder cancer. Furthermore, the impact of intravesical instillations on bladder function will be examined by urodynamic examination both prior to and following instillation therapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04943094
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-muscle Invasive Bladder Cancer
Currently open trials in the same condition.
- NCT07206225 — A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer · Phase 1 · recruiting
- NCT06503614 — A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
- NCT06632964 — A Clinical Trial Aimed at Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder C · Phase 1 · recruiting
- NCT07252297 — The Role of Universal Cancer Only Marker SIX6 in Diagnosing Non-Muscle Invasive Bladder Cancer · NA · active not recruiting
- NCT04165317 — A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer · Phase 3 · active not recruiting
Other Aarhus University Hospital trials
Trials by the same sponsor.
- NCT07432802 — Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer · NA · not yet recruiting
- NCT07499336 — UNDERSTANDING THE T-CELL AND B-CELL RECEPTOR REPERTOIRE IN CHILDREN AND YOUNG ADULTS WITH ANTI-DRUG ANTIBODIES AGAINST P · not yet recruiting
- NCT07454486 — TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cance · not yet recruiting
- NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
- NCT07426250 — Clinical Utility of ctDNA in the Treatment of Oligometastatic Disease · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04943094 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aarhus University Hospital
- Last refreshed: 31 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04943094.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing